Pandorum and MUSC (Translational Research and Immunobiology Institute-TRII) collaboration structure aimed for accelerated clinical translation in the US. (A) Our first clinical study “SAMPSON 1” –is an early stage open label study in the patients with COVID-19 induced ARDS, using Umbilical Cord derived Mesenchymal Stem Cell Therapy – has been recently approved by IRB, and awaiting FDA IND application. The study will also generate an FDA approved clinical grade human UCMSC cell bank for Pandorum, that will be used for the development of advanced cell derived exosome therapeutics using our proprietary ‘Cell farming’ platform. (B) Dr. Satish N. Nadig MD, PhD, FACS (fourth from the right) Associate Professor Surgery at MUSC and the Director of Center for Cellular Therapy (CCT)- an FDA registered cGMP facility for cell therapy, is leading the collaboration. Dr. Nadig is also the Chief Medical Advisor to Pandorum US.
Dr. Shroff’s Charity Eye Hospital is one of the top specialty eye hospitals in India, with a long history of creating impact in ophthalmological space. Dr. Virender Sangwan has been guiding Pandorum’s corneal translational project at Shroff. Our animal studies are being conducted at Dabur Research Foundation (DRF) – a leading Indian contract research organization.